health pharma news today obesity drugs glp-1 Popular medications may have benefits that extend beyond weight loss and blood sugar control, a new study finds Late-stage obesity drugs 2026 |
Description
BARRIERS TO SWITCHING FROM ONE GLP1RA TO ANOTHER Patients may be reluctant to switch between GLP1RAs
Cambi MPC, Baretta GAP, Magro DDO, Boguszewski CL, Ribeiro IB, Jirapinyo P, de Moura DTH
Both are considered advanced basal insulin options for patients who need long-acting glucose coverage
doi: 10.1186/s12943-024-02140-6 [DOI] [PMC free article] [PubMed] [Google Scholar] 68
As awareness about newer treatment options rises among both healthcare professionals and patients, adoption of these therapies continues to expand
